Spero Therapeutics Files Routine 8-K, Confirms Nasdaq Listing

Ticker: SPRO · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1701108

Spero Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySpero Therapeutics, Inc. (SPRO)
Form Type8-K
Filed DateJan 5, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $76.3 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: compliance, corporate-governance, administrative

TL;DR

**SPRO filed a routine 8-K, confirming its Nasdaq listing and compliance.**

AI Summary

Spero Therapeutics, Inc. filed an 8-K on January 5, 2024, to report on its current status, including its common stock trading on The Nasdaq Global Select Market under the symbol SPRO. This filing primarily serves as a routine update, confirming the company's operational details and compliance with SEC regulations. For investors, this matters because it indicates the company is maintaining its listing and fulfilling its disclosure obligations, which is a basic requirement for public companies and suggests ongoing business operations.

Why It Matters

This filing confirms Spero Therapeutics' continued compliance with SEC reporting requirements and its listing on The Nasdaq Global Select Market, providing basic assurance of its public company status.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not contain information that introduces new or significant risks to investors.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material changes or events, and would look to other filings for substantive business updates.

Key Numbers

  • $0.001 — par value per share (This is the stated par value of Spero Therapeutics' common stock.)

Key Players & Entities

  • Spero Therapeutics, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Global Select Market (company) — the exchange where Spero Therapeutics' common stock is registered
  • SPRO (company) — the trading symbol for Spero Therapeutics' common stock
  • $0.001 (dollar_amount) — par value per share of common stock
  • January 5, 2024 (date) — Date of earliest event reported and filing date

Forward-Looking Statements

  • Spero Therapeutics will continue to trade on The Nasdaq Global Select Market. (Spero Therapeutics, Inc.) — high confidence, target: 2025-01-05

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant as specified in its charter is SPERO THERAPEUTICS, INC.

What is the trading symbol for Spero Therapeutics, Inc. common stock?

The trading symbol for Spero Therapeutics, Inc. common stock is SPRO.

On which exchange is Spero Therapeutics, Inc. common stock registered?

Spero Therapeutics, Inc. common stock is registered on The Nasdaq Global Select Market.

What is the par value per share of Spero Therapeutics, Inc. common stock?

The par value per share of Spero Therapeutics, Inc. common stock is $0.001.

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was January 5, 2024.

Filing Stats: 879 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-01-05 08:11:05

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se
  • $76.3 million — of December 31, 2023 were approximately $76.3 million. The following information should be co

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. As part of its press release, as described below, Spero Therapeutics, Inc. (the "Company") disclosed that its cash and cash equivalents as of December 31, 2023 were approximately $76.3 million. The following information should be considered in connection with this preliminary result: The Company's audited, consolidated financial statements as of December 31, 2023, are not yet available. Accordingly, the information presented above reflects the Company's preliminary estimate, subject to the completion of the Company's financial closing procedures and the annual audit of its financial statements by its auditors. As a result, this preliminary estimate may differ from the actual results that will be reflected in the Company's audited, consolidated financial statements for the fiscal year ended December 31, 2023 when they are completed and publicly disclosed. This preliminary estimate may change, and that change may be material. The Company's independent registered public accountants have not audited, reviewed or performed any procedures with respect to such preliminary estimate and accordingly do not express an opinion or any other form of assurance with respect thereto.

01

Item 7.01. Regulation FD Disclosure. On January 5, 2024, the Company issued a press release entitled "Spero Therapeutics Provides Corporate Update and 2024 Outlook" (the "Press Release"). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report"). In addition, on January 5, 2024, the Company updated its investor presentation (the "Investor Presentation"), which the Company expects to use in connection with general corporate presentations and will be made available on the Company's website or distributed by the Company in hardcopy or electronic form. A copy of the Investor Presentation is attached as Exhibit 99.2 to this Current Report. The Investor Presentation is current as of January 5, 2024, and the Company disclaims any obligation to update the Investor Presentation after such date. In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01, the Press Release, and the Investor Presentation is "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.

01

Item 8.01 Other Events. Tebipenem HBr As previously reported, the Company achieved first patient, first visit in PIVOT-PO, the global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), with a target enrollment of approximately 2,648 patients, which the Company expects to be completed in the second half of 2025. Cash Runway Guidance The Company believes its cash and cash equivalents as of December 31, 2023, together with the development milestone payments due under its license agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK), will be sufficient to fund anticipated operating and capital expenditure requirements into late 2025.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated January 5, 2024. 99.2 Investor Presentation of Spero Therapeutics, Inc. dated January 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 5, 2024 SPERO THERAPEUTICS, INC. By: /s/ Tamara Joseph Tamara Joseph Chief Legal Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.